NASDAQ: SNTI - Senti Biosciences, Inc.

Rentabilidad a seis meses: +0.5128%
Rendimiento de dividendos: 0.00%
Sector: Healthcare

Calendario de promoción Senti Biosciences, Inc.

Horario avanzado gráfico sencillo
Financial Markets by TradingView

Acerca de la empresa Senti Biosciences, Inc.

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.

más detalles
The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Añadir a la lista de comparación
Añadir a la lista de vigilancia
Añadir al portafolio
Añadir aviso de precio

IPO date 2022-06-09
ISIN US81726A1007
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.sentibio.com
Цена ао 0.412
Cambio de precio por día: -5.31% (4.14)
Cambio de precio por semana.: -1.26% (3.97)
Cambio de precio por mes: +83.18% (2.14)
Cambio de precio en 3 meses.: +73.45% (2.26)
Cambio de precio en seis meses: +0.5128% (3.9)
Cambio de precio por año: +493.94% (0.66)
Cambio de precio en 3 años.: -60.32% (9.88)
Cambio de precio en 5 años.: 0% (3.92)
Cambio de precio en 10 años.: 0% (3.92)
Cambio de precio desde principios de año.: +85.78% (2.11)
Todos los parámetros

Subestimación

Nombre Significado Calificación
P/S 9.51 1
P/BV 0.3641 10
P/E 0 0
EV/EBITDA -0.4243 0
Total: 5

Eficiencia

Nombre Significado Calificación
ROA, % -59.47 0
ROE, % -106.19 0
Total: 0

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0

Deber

Nombre Significado Calificación
Debt/EBITDA -0.6122 10
Total: 10

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % 2912.94 10
Rentabilidad Ebitda, % 186.62 10
Rentabilidad EPS, % 1244.77 10
Total: 10
Más detalles

Instituciones Volumen Compartir, %
NEA Management Company, LLC 4426151 9.67
8vc Gp I, LLC 2537558 5.55
ARK Investment Management, LLC 1969860 4.31
Vanguard Group Inc 707052 1.55
Intel Corporation 595665 1.3
Triatomic Management Lp 310533 0.68
Geode Capital Management, LLC 238406 0.52
Omega Fund Management, Llc 195792 0.43
Bridgeway Capital Management, Inc. 145000 0.32
Artal Group S.A. 55555 0.12



Supervisor Título profesional Pago año de nacimiento
Dr. Timothy K. Lu M.D., Ph.D. Co-Founder, CEO & Director 868.57k 1981 (44 año)
Dr. James J. Collins Ph.D. Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director 58.5k 1966 (59 años)
Dr. Kanya Rajangam M.D., Ph.D. President, Head of Research & Development and Chief Medical Officer 689.99k 1974 (51 año)
Dr. Wilson Wong Ph.D. Scientific Co-Founder & Member of Scientific Advisory Board N/A
Ms. Yvonne Li M.B.A. Interim CFO, Treasurer & Principal Accounting Officer 1960 (65 años)
Mr. Thomas P. Chung Vice President of Strategic Finance & Corporate Development
Ms. Dee Olomajeye Dragon Vice President of People Strategy & Culture

DIRECCIÓN: United States, South San Francisco. CA, 2 Corporate Drive - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.sentibio.com